NC-AVAYA
12.4.2021 12:02:08 CEST | Business Wire | Press release
Avaya (NYSE: AVYA), a global leader in solutions to enhance and simplify communications and collaboration, today released the results of a new survey, “Life and Work Beyond 2020: The Change Makers,” examining how attitudes and feelings toward home and work life have changed over the last year. The Avaya survey uncovers a significant happiness gap, with only 27% of respondents saying they were happier in 2020 and 43% saying they were less happy. The survey also reveals that organizations have the power to increase well-being, with 56% saying hybrid work has the potential to improve their well-being and 79% saying that when engaging with an organization’s contact center, they expect agents to do everything possible to make them happy.
Digital transformation and the pandemic have created lasting change in how we want to work and shop. As workers, we want a hybrid work environment that offers more choice and eliminates an inflexible daily grind. As consumers, we want to interact with businesses through the channels we prefer, and we expect in-the-moment responsiveness to address our unique needs. Businesses that want to meet these changing dynamics require composable solutions that let them build the ideal communications and collaboration environment for managing distributed teams and empowering these teams to delight customers.
“Avaya’s ‘Life and Work Beyond 2020’ survey presents a compelling case that organizations today play a critical role in our well-being, both as employers and service providers,” said Simon Harrison, Chief Marketing Officer, Avaya. “The question is, how can businesses enable hybrid work while ensuring employees have the tools they need to consistently delight customers? Avaya OneCloud is a composable communication and collaboration platform that enables businesses to bridge employee and customer experiences, with fluid, seamless engagement no matter where employees are working while empowering them to quickly create and deliver memorable experiences in the moment.”
Key Takeaways from Avaya’s “Life and Work Beyond 2020” Survey
Our sources of happiness are changing – and many are less happy
According to the survey, the unsurprising top sources of decreased happiness in 2020 include the COVID-19 pandemic (82%), less face-to-face contact with others (68%) and money worries (64%). However, among the 27% of respondents whose happiness increased, the top reasons included some surprises, including flexibility in deciding where to work (62%) and more work from home & bosses trusting workers (57%).
Work needs flexibility
The desire for more work flexibility is underscored by the fact that across all respondents, 46% feel trapped in a daily routine and 43% are struggling to find the right work-life balance. Further, 56% think that hybrid work will have the potential to improve their well-being, and 60% would support government policies that embrace hybrid working.
Changed values are reshaping how we shop
Honesty, respect and optimism are now top values, and 69% of respondents say they actively (33%) or sometimes (36%) choose organizations, including banks, retailers, utilities, healthcare providers, and telecom providers, that reflect their values. More than 1 out of 2 prefer a mix of ways to contact organizations, including a phone number on every webpage or app (69%) and more help available on websites (57%). Nearly half of respondents (47%) say convenience is more important than price.
Organizations have a big impact on our well-being
The impact of organizations on well-being is huge, with 71% of respondents saying customer service problems cause them a great deal (28%) or a considerable amount (43%) of stress. A full 79% expect organization contact centers to do everything possible to make them a happy customer, but only 13% say organizations always make them feel good after an interaction and only 8% say they are regularly delighted by their interactions.
The survey, conducted in November 2020, is based on interviews with 10,000 consumers and workers in a variety of markets around the world, including Austria, Canada, Egypt, France, Germany, India, Saudi Arabia, Switzerland, UAE, the UK and the U.S.
Additional Resources
- Learn how Avaya OneCloud solutions can make an impact in your organization.
- Check out the full Life and Work Beyond 2020: The Change Makers report.
- See the infographic, How our values, relationships with businesses and working lives are changing .
About Avaya
Businesses are built by the experiences they provide, and everyday millions of those experiences are delivered by Avaya Holdings Corp. (NYSE: AVYA). Avaya is shaping what's next for the future of work, with innovation and partnerships that deliver game-changing business benefits. Our cloud communications solutions and multi-cloud application ecosystem power personalized, intelligent, and effortless customer and employee experiences to help achieve strategic ambitions and desired outcomes. Together, we are committed to help grow your business by delivering Experiences that Matter. Learn more at http://www.avaya.com/
Cautionary Note Regarding Forward-Looking Statements
This document contains certain “forward-looking statements.” All statements other than statements of historical fact are “forward-looking” statements for purposes of the U.S. federal and state securities laws. These statements may be identified by the use of forward looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," “our vision,” "plan," "potential," "preliminary," "predict," "should," "will," or “would” or the negative thereof or other variations thereof or comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. The factors are discussed in the Company’s Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) available at www.sec.gov , and may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. The Company cautions you that the list of important factors included in the Company’s SEC filings may not contain all of the material factors that are important to you. In addition, in light of these risks and uncertainties, the matters referred to in the forward-looking statements contained in this press release may not in fact occur. The Company undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.
All trademarks identified by ®, TM, or SM are registered marks, trademarks, and service marks, respectively, of Avaya Inc. All other trademarks are the property of their respective owners.
Source: Avaya Newsroom
View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005185/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
